Nanomedicine: Nanotechnology, Biology and Medicine Welcomes New Editor-in-Chief

Editor-in-Chief Lajos P. Balogh, PhD to lead online journal

Philadelphia, 5 March 2009 – Elsevier is honored to announce today that Lajos P. Balogh, PhD, has been named the new Editor-in-Chief of Nanomedicine: Nanotechnology, Biology and Medicine, an online journal published by Elsevier.

Dr. Balogh has been involved in nanotechnology research since 1996 and is presently active in various interdisciplinary directions. His major research interest is the construction of well-defined organic/inorganic hybrid medical nanodevices for targeted detection, imaging, and biophysical therapy of cancer based on dendrimers, smart contrast agents, and radioactive nanocomposites. He has published over 180 scientific papers and has been awarded 12 patents on dendrimers, nanocomposites, cancer imaging and treatment, analytical chemistry, separation science, technology, polymer synthesis and characterization.

Dr. Balogh is currently a Professor of Biomedical Nanotechnology and Director of Nanotechnology Research in the Department of Radiation Medicine at the Roswell Park Cancer Institute, Buffalo, NY. He is also the Co-Director of the NanoBiotechnology Center at Roswell and Professor of Oncology at the University at Buffalo, SUNY.

Kate Williamson, Elsevier Associate Publisher for Nanomedicine: Nanotechnology, Biology and Medicine, commented: “We are so pleased to welcome Dr. Balogh as Editor-in-Chief of Nanomedicine: NBM. Dr. Balogh's expertise in the field will be a tremendous asset to the journal. We look forward to working with Dr. Balogh and the editorial team to carry out his vision for the journal.”

# # #

About Nanomedicine: Nanotechnology, Biology and Medicine
Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is an international, peer-reviewed journal. Each quarterly issue of Nanomedicine: NBM presents basic, clinical, and engineering research in the field of nanomedicine. Article categories include basic, diagnostic, experimental, clinical, engineering, pharmacologic, and toxicologic nanomedicine. The Journal is indexed in MEDLINE from Volume 1, issue 1 and is available online at www.nanomedjournal.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media Contact:
Caroline Foote
Elsevier
+1 215 239 3652
c.foote@elsevier.com